-transparent.png){kind=logo}
Levels of C3, properdin, factor B, and C3 to C9 activity were markedly reduced in cord sera taken from 94 normal newborn infants. Nevertheless, cord serum supported complete activation of its own alternative pathway by zymosan or CoF. Lysis of a target cell, however, was defective; nearly 75% of cord sera had reduced rabbit erythrocyte CH50 titers. These were partially increased by the addition of factor B and properdin, and totally restored by adding factor B, properdin, and C3 to C9. Therefore, although the alternative pathway of the neonate is intact, it appears to be limited in its ability to generate an adequate number of stable and active enzymatic sites on a target cell membrane.
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
December 1979,
Pediatric research,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
October 1977,
The Journal of pediatrics,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
November 1979,
Pediatrics,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
August 1983,
Pediatric research,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
December 1976,
Experientia,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
January 1986,
Mead Johnson Symposium on Perinatal and Developmental Medicine,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
December 1983,
Pathologie-biologie,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
May 1984,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
January 1984,
Springer seminars in immunopathology,
D Adamkin, and
A Stitzel, and
J Urmson, and
M L Farnett, and
E Post, and
R Spitzer
October 2019,
Biochemia medica,
